Acalabrutinib with Boceprevir Interaction Details
Brand Names Associated with Acalabrutinib
- Acalabrutinib
- Calquence®
Brand Names Associated with Boceprevir
- Boceprevir
- Victrelis®
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Feb 25, 2024
Interaction Effect
Increased acalabrutinib exposure
Interaction Summary
Avoid long-term use of acalabrutinib with a CYP3A strong inhibitor; if short-term use of CYP3A stong inhibitor is required, interrupt acalabrutinib. Coadministration of itraconazole, a strong CYP3A inhibitor, with acalabrutinib resulted in an increase of acalabrutinib Cmax and AUC[1].
Severity
Major
Onset
Unspecified
Evidence
Probable
How To Manage Interaction
Avoid long-term coadministration of acalabrutinib with a CYP3A strong inhibitor as acalabrutinib exposure may be increased. If short-term use of CYP3A stong inhibitor is required, interrupt acalabrutinib[1].
Mechanism Of Interaction
Inhibition of CYP3A-mediated metabolism of acalabrutinib
Literature Reports
A) Coadministration of itraconazole, a strong CYP3A inhibitor, 200 mg/day for 5 days with acalabrutinib resulted in an increase of acalabrutinib Cmax and AUC by 3.9- and 5.1-fold, respectively [1].
References
1 ) Product Information: CALQUENCE(R) oral capsules, acalabrutinib oral capsules. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2017.
Acalabrutinib Overview
-
Acalabrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used alone or with obinutuzumab (Gazyva) to treat chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL: a type of cancer that begins in the white blood cells). Acalabrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Boceprevir Overview
-
Boceprevir is used along with two other medications (ribavirin [Copegus, Rebetol] and peginterferon alfa [Pegasys]) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in people who have not yet been treated for this condition or whose condition did not improve when they were treated with ribavirin and peginterferon alfa alone. Boceprevir is in a class of medications called protease inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Boceprevir may not prevent the spread of hepatitis C to other people.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.